Genmab A/S
CSE:GMAB
Gross Margin
Genmab A/S
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Gross Margin Across Competitors
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Genmab A/S
CSE:GMAB
|
86.6B DKK |
95%
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
0%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.7B USD |
70%
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
169.7B USD |
62%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
133.4B USD |
78%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
129.3B USD |
86%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
76%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
123B AUD |
52%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
72.2B USD |
87%
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
75%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
36.6B USD |
86%
|
Genmab A/S
Glance View
In the world of biotechnology, Genmab A/S has carved a niche as a leader in the development and innovation of antibody therapeutics. Established in Denmark in 1999, the company has focused on harnessing the power of antibodies to create novel treatments for cancer and other serious diseases. Genmab's approach is both scientific and strategic, leveraging its proprietary DuoBody and HexaBody platforms to engineer antibodies that are designed to enhance effectiveness and reduce side effects. This innovative focus has not only set Genmab apart as a pioneer in immunotherapy but has also yielded a rich pipeline of products, several of which have gained regulatory approval and found a place in global markets. Genmab's business model is built on a foundation of collaboration and strategic partnerships with major pharmaceutical companies, including heavyweights such as Janssen and Roche. These alliances are crucial as they provide the financial support needed for large-scale clinical trials and access to global distribution networks. Revenue streams primarily flow from milestone payments, licensing fees, and royalties generated from successful therapies. The company's notable blockbuster, Darzalex, a treatment for multiple myeloma, continues to be a significant revenue driver, exemplifying Genmab's capacity to transform scientific discovery into economic success. Through this blend of innovation, strategic partnerships, and commercialization, Genmab maintains a robust business while keeping its dedication to pioneering treatments at the forefront of its mission.
See Also
Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.
Based on Genmab A/S's most recent financial statements, the company has Gross Margin of 95.4%.
You don't have any saved screeners yet